2022 the Japanese Society of Medical Oncology Annual Meeting

Session information

Print

Mini-Oral Session

[MO6] Mini-Oral Session 6　Hepatobiliary / Pancreatic Cancer 3（Pancreatic Cancer 2）
【E】

Thu. Feb 17, 2022 2:10 PM - 3:00 PM Room 6 (Room D, 1F, Kyoto International Conference Center)

Chair：Akiko Todaka（Division of Gastrointestinal Oncology, Shizuoka Cancer Center），Kohei Nakachi（Department of Medical Oncology, Tochigi Cancer Center）

[MO6-1] Real-world treatment outcomes of metastatic pancreatic cancer in Japan: Tokushukai REAl-world Data project 03(TREAD 03)

○Rai Shimoyama1, Yoshinori Imamura2, Kiyoaki Uryu3, Takahiro Mase4, Yoshiaki Fujimura5, Maki Hayashi6, Megu Ohtaki7, Keiko Otani7, Nobuaki Shinozaki1,8, Hironobu Minami2 (1.Department of General Surgery, Shonankamakura General Hospital, 2.Department of Medical Oncology and Hematology, Kobe University Graduate School of Medicine, 3.Department of Medical Oncology, Yao Tokushukai General Hospital, 4.Department of Breast Surgery, Ogaki Tokushukai Hospital, 5.Tokushukai Information System Inc., 6.Mirai Iryo Research Center Inc., 7.deCult Co., Ltd., 8.General Incorporated Association Tokushukai)

[MO6-2] Post-approval clinical experience with anamorelin for pancreatic cancer patients

○Mao Okada2, Akihiro Ohba2, Natsumi Yamada2, Yumi Murashima2, Yuki Kawasaki2, Kotaro Takeshita2, Kosuke Maehara2, Tomoyuki Satake2, Yuta Maruki2, Yoshikuni Nagashio2, Shunsuke Kondo2, Susumu Hijioka2, Chigusa Morizane2, Hideki Ueno2, Takuji Okusaka2 (1.National Cancer Center Hospital, 2.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital)

[MO6-3] Clinical and biological results of tocilizumab + rechallenge-gemcitabine/nab-paclitaxel for metastatic pancreatic cancer

○Shuichi Mitsunaga1,2, Ikeda Masafumi1, Aoki Kazunori3, Imaoka Hiroshi1, Sasaki Mitsuhito1, Watanabe Kazuo1, Ochiai Atsushi2, Yamaguchi Kyoko4, Sawada Noriaki5, Fujii Etsuko6, Nishidate Masanobu4, Fujitomo Takashi6, Mizuno Hideaki6, Kayukawa Yoko5, Makikawa Mayu4, Tsunoda Hiroyuki6, Terao Kimio4 (1.Department of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, 2.Division of Biomarker Discovery, Exploratory Oncology Research & Clinical Trial Center, National Cancer Center, 3.Division of Molecular and Cellular Medicine, National Cancer Center, 4.Pharmaceutical Science Dept, Chugai Pharmaceutical Co., Ltd, 5.Discovery Pharmacology Dept, Chugai Pharmaceutical Co., Ltd, 6.Discovery Technology Dept, Chugai Pharmaceutical Co., Ltd)